Press Releases

• December 6, 2012
  

  The National Multiple Sclerosis Society and Critical Path Institute Create the Multiple Sclerosis Outcome Assessments Consortium

• October 1, 2012
  

  Launch of the Good Participatory Practice Guidelines for TB Drug Trials

• June 21, 2012
  

  CDISC, C-Path and FDA Collaborate to Develop Data Standards to Streamline Path to New Therapies

  The Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute (C-Path) announce the signing of a partnership sagreement to establish the Coalition For Accelerating Standards and Therapies, or CFAST, an initiative to accelerate clinical research and medical product development by creating and maintaining data standards, tools and methods for conducting research in therapeutic...
• January 23, 2012
  

  European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials

  Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has issued a positive opinion on the use of magnetic resonance imaging (MRI) to measure hippocampal volume as a tool to enrich recruitment into regulated clinical...
• November 9, 2011
  

  Launch of the Critical Path to TB Drug Regimens’ Advisory Panel